CARE Research, LLC Chooses Science Exchange as the Primary Online Channel to Offer Preclinical In Vivo Services to Scientists

lab-mouse

PALO ALTO, CA, March 6, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a partnership with CARE Research, LLC to offer online access to its preclinical services to scientists around the globe. CARE Research, LLC is a Colorado-based contract research organization (CRO) and a […]

Read More…

Tech Q&A with CARE Research

lab-mouse

Chandreyee Das, PhD, of Science Exchange recently spoke with Rajan Bawa, PhD, of CARE Research LLC, a leading preclinical CRO combining quality service for clients with excellent quality of life for animals — even for challenging or complex projects. CD: Rajan, you’ve been in the pharmaceutical and biotechnology industry for over 40 years, can you […]

Read More…

Tech Q&A with Likarda, LLC

3D Drug Screening

Guru Singh, Director of Scientific Content, recently spoke with Dr. Lisa Stehno-Bittel, President and Founder of Likarda LLC, an exciting biotech service company on the Science Exchange network.     GS: Nice to meet you, Lisa! Why do clients come to Likarda? LSB: Likarda is the company you come to when your scientific questions require […]

Read More…

New on Science Exchange: VR Tech, Cancer Genetics, Stem Cell-based Organoids

futuristic

Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | blog.scienceexchange.com Virtual Reality Software: Explore biology at nanoscale From “Fantastic Voyage” (1966) to “A Wind in the Door” (1973), fiction has adored the idea of exploring the body at cellular and molecular levels. Now, virtual reality (VR) software, combined with the computational power afforded by blockchain […]

Read More…

Small Biotech Stories: Eos Neuroscience

neuroscience

Eos Neuroscience is a company built on collaboration, featuring a unique team with expertise in transgenes, virology and gene expression, and retinal degeneration. Once they complete their preclinical stage, their intended userbase would be those with blindness attributed to photoreceptor degeneration, or age-related macular degeneration. They are running into some problems in the process of […]

Read More…